News & Resources / All News

Veredus Laboratories Announces CE-IVD Marking of VereCoV™ Detection Kit for Diagnosis of COVID-19

Veredus Laboratories Pte Ltd “Veredus” today announced the CE-IVD marking of VereCoV™ Detection Kit for commercial launch in Europe. The test is intended for the qualitative detection of 2019 novel Coronavirus (2019-nCoV) also known as SARSCoV- 2 that causes COVID-19.

The kit was developed to provide an easy-to-use solution for clinical testing, public health surveillance and detection of the coronavirus from nasal or nasopharyngeal swab specimen to enable authorities to take appropriate actions. The test integrates PCR amplification and microarray for rapid qualitative detection of 2019-nCoV with the additional capability to detect a subset of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) simultaneously with the same test.

“We are ready to respond effectively to the needs of hospitals and reference laboratories by providing a quality molecular testing solution for the pandemic,” says Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories.

A pilot study: VereMTB detection kit for rapid detection of multidrug-resistant mycobcterium tuberculosis in clinical sputum samples

The performance of VereMTBTM Detection Kit for detection of multidrug-resistant tuberculosis (MDR-TB) was validated by using 124 sputum samples. Comparing with MGIT culture, the sensitivity and specificity of VereMTB Detection Kit for MTBC detection were 97.0% and 98.3%, respectively. Compared with MGIT DST, the sensitivity and specificity of VereMTB Detection Kit for RIF resistance detection were 85.7% and 93.9%, respectively, and the sensitivity and specificity of VereMTB Detection Kit for INH resistance detection were 75.0% and 95.7%, respectively. 6 NTM samples were also detected and identified correctly. The VereMTB Detection Kit can detect MDR-TB rapidly and accurately in sputum samples from TB suspects.

Click here to read more

Veredus Laboratories to support the bio-surveillance detection of 2019-nCoV (SAR-CoV-2) at Singapore checkpoints

In the light of recent developments related to the ongoing COVID-19 outbreak, Veredus Laboratories is supporting the bio-surveillance detection efforts by swab tests from travellers at land, sea and air checkpoints in Singapore. Using the VerePLEX™ Biosystem that utilises the Lab-on-Chip technology, the VereCoV™ Detection Kit is used for the multiplexed screening and detection of the viral nucleic acid.

For more information on the additional precautionary measures in response to the global situation of escalating COVID-19 infection, please refer to the Ministry of  Health Singapore website at to find out more.

Learn more about the swab test that has been implemented at Singapore checkpoints beginning 4March 2020 at .

Veredus Laboratories’ VereCoV™ Detection Kit receives Singapore HSA Provisional Authorisation for IVD use

Veredus Laboratories Pte Ltd “Veredus” has obtained the Provisional Authorisation from Singapore Health Sciences Authority (HSA) for its VereCoV™ Detection Kit following Veredus’ rapid launch of this kit as a “Research Use Only” (RUO) test earlier this year. With this Authorisation, VereCoV™ Detection Kit can be used directly by laboratories or hospitals to test patients for clinical diagnosis.

Veredus Laboratories Announces the Development of a Lab-on-Chip for the detection of 3 coronaviruses: MERS-CoV, SARS-CoV and 2019-nCoV

Veredus Laboratories Pte Ltd “Veredus”, a leading provider of innovative molecular diagnostic solutions, announced today the development of VereCoV detection kit, a portable Lab-on-Chip application capable of detecting the Middle-East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and 2019 Novel Coronavirus (2019-nCoV) i.e. Wuhan Coronavirus, in a single test.